from seed
to summit.
We fuel the ascent of tech and biotech pioneers.
Investing in pre-seed and seed stage startups scaling the highest peaks of innovation.
Teams We're Backing
.png)
Fauna Bio is harnessing 100 million years of evolution to cure human disease. Using its proprietary Convergence™ AI platform, the company analyzes genomic data from animals that have naturally evolved to resist specific illnesses. By identifying and replicating these disease-resistant mechanisms, Fauna Bio discovers novel drugs for humans, with its lead asset targeting heart disease associated with Pulmonary Hypertension.​
​
Read more here.
Modulate Bio's AI-powered discovery platform is engineered to overcome the limitations of current neurological treatments. By precisely designing novel GABAA positive allosteric modulators, the company is developing a pipeline of differentiated therapies for Essential Tremor, epilepsy, and anxiety that promise greater efficacy without the common side effects of today's standards of care.
​
Read more here.
.
.png)
Company to be announced soon
Our Team
Managing Partner
Colin Maraganore
Colin brings a unique operator-investor perspective to venture capital as a founding Principal of Abeja Ventures’ $125M emerging biotechnology fund, where he and Nelly co-led the evaluation of 200+ annual opportunities and explored co-investment opportunities with 100+ institutional partners. His hybrid expertise stems from 9 years of hands-on leadership at now clinical-stage biotechs – including BioAge Labs, Rejuvenation Technologies, and Earli, Inc. – giving him rare operational fluency in therapeutic development from preclinical validation through clinical translation. Colin holds a BS in Psychology and Neuroscience from the University of Minnesota.
Managing Partner
Nelly Weiser
A bioengineer by training and passion, Nelly was a founding member and Principal at Abeja Ventures, a $125M emerging biotechnology VC fund investing in Series A therapeutics and digital health companies. She brings deep expertise in designing, building, and investing in innovative ventures. Prior to Abeja, Nelly was a Strategy and Operations Lead at Moment Biosciences, an mRNA therapeutics company, and held research positions at Earli, Inc. and the Khalil Lab at Boston University. Nelly is also an angel investor, having previously invested in companies such as Ripple Foods and Zus Health. Nelly holds a BS from Stanford and a MS in Bioengineering from BU.
Managing Partner
Ishtpreet Singh
Ishtpreet brings a uniquely multifaceted perspective to early-stage investing, drawing from extensive experience in Silicon Valley and politics. With over 8 years at Google and Waymo, he has driven critical initiatives in policy, government affairs, and product strategy. His political acumen was honed through service on White House Advance Teams for two U.S. Presidents. Ishtpreet’s venture capital experience includes 20% work with GV (Google Ventures), a top tier firm. As a prolific angel investor, he has built a portfolio of 50 companies. Ishtpreet holds an MBA from the University of Chicago Booth School of Business, complementing his strong foundation in technology and policy.
_edited.png)
